Home > Journals > Panminerva Medica > Past Issues > Articles online first > Panminerva Medica 2020 Dec 04

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Panminerva Medica 2020 Dec 04

DOI: 10.23736/S0031-0808.20.04079-3

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Novel insights on lymphoma and lymphomagenesis in primary Sjögren’s Syndrome

Alessia ALUNNO 1, Maria Comasia LEONE 2, Elena BARTOLONI 1, Roberto GERLI 1, Francesco CARUBBI 3

1 Rheumatology Unit, University of Perugia, Perugia, Italy; 2 Rheumatology Unit, S. Maria Hospital, Terni, Italy; 3 COVID-19 Medicine Unit, Medicine Department, ASL1 Avezzano-Sulmona-L’Aquila, L’Aquila, Italy


PDF


INTRODUCTION: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by a chronic inflammatory process mainly affecting the exocrine glands but also burdened by a wide range of extraglandular manifestations. Non-Hodgkin lymphoma (NHL) is the most severe pSS complication worsening disease prognosis.
EVIDENCE ACQUISITION: We summarized original articles published between April 2018 and May 2020 on this topic aiming to highlight novelties on lymphoma and lymphomagenesis.
EVIDENCE SYNTHESIS: Results have been grouped by epidemiology, etiopathogenesis and predictors of lymphoma.
CONCLUSIONS: NHL is the most severe complication of pSS and occurs in around 5-10% of patients. Over the last two years, several clinical, serological, and histopathological features have been proposed as predictive for lymphoma in pSS patients, allowing early diagnosis and consequently, better management and prognosis. Individual monitoring for disease activity and possible lymphoma development is a central clue in the evaluation of pSS patients.


KEY WORDS: Sjögren’s syndrome; non-Hodgkin lymphoma; MALT lymphoma; B lymphocytes

top of page